A Phase 1 interventional study of Dabigatran etexilate and Dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-20.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the relative bioavailability of dabigatran etexilate as pellets on food and of dabigatran etexilate as granules resolved in reconstitution solution, each with dabigatran etexilate as capsule following oral administration. To evaluate acceptability and palatability of Pellets sprinkled on food and Oral Liquid Formulation
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
multiple dose of dabigatran
Drug: Dabigatran etexilate
multiple dose of dabigatran
Drug: Dabigatran etexilate
multiple dose of dabigatran
Drug: Dabigatran etexilate
Pellets (multiple dose of dabigatran)
Granules resolved in reconstitution solution (multiple dose of dabigatran)
Hard capsule (multiple dose of dabigatran)
Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.
Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.
Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.
Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.
Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Acceptability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.
Acceptability question: "Would you accept to take this medication for chronic use?" with 3 possible answers: Yes - No - I am not sure.
Time frame: once on day 3 (48 hours after first dose)
Palatability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.
Palatability question: "How do you rank the taste?" with 5 possible answers: Very good - Good - Fair - Acceptable - Not acceptable.
Time frame: once on day 3 (48 hours after first dose)
| Milestone | T1-T2-R | T1-R-T2 | T2-T1-R | T2-R-T1 | R-T1-T2 | R-T2-T1 |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.
| ng∙h/mL | T1 (Treatment A) | T2 (Treatment B) | R (Reference) |
|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran. | 1220 ± 34.1 | 1160 ± 27.0 | 893 ± 46.8 |
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.
| ng/mL | T1 (Treatment A) | T2 (Treatment B) | R (Reference) |
|---|---|---|---|
| Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran. | 191 ± 37.4 | 184 ± 27.3 | 131 ± 50.8 |
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.
| ng*h/mL | T1 (Treatment A) | T2 (Treatment B) | R (Reference) |
|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran. | 1000 ± 35.8 | 958 ± 27.6 | 727 ± 50.8 |
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.
| ng/mL | T1 (Treatment A) | T2 (Treatment B) | R (Reference) |
|---|---|---|---|
| Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran. | 157 ± 37.9 | 154 ± 27.6 | 106 ± 55.1 |
Acceptability question: "Would you accept to take this medication for chronic use?" with 3 possible answers: Yes - No - I am not sure.
| participants | T1 (Treatment A) | T2 (Treatment B) |
|---|---|---|
| Yes | 37 | 29 |
| No | 9 | 17 |
| I am not sure | 7 | 7 |
Palatability question: "How do you rank the taste?" with 5 possible answers: Very good - Good - Fair - Acceptable - Not acceptable.
| participants | T1 (Treatment A) | T2 (Treatment B) |
|---|---|---|
| Very good | 2 | 0 |
| Good | 20 | 15 |
| Fair | 18 | 17 |
| Acceptable | 11 | 14 |
| Not acceptable | 2 | 7 |
Collected over First dose of study drug date/time until the end-of-trial examination (last per protocol visit). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T1 (Treatment A) | — | 0/54 (0%) | 2/54 (3.7%) |
| T2 (Treatment B) | — | 0/54 (0%) | 3/54 (5.6%) |
| R (Reference) | — | 0/54 (0%) | 1/54 (1.9%) |
| Event | T1 (Treatment A) | T2 (Treatment B) | R (Reference) |
|---|---|---|---|
| HeadacheNervous system disorders | 2/54 | 3/54 | 1/54 |
The evaluation of demographic and baseline characteristics were performed on the treated set which included all subjects who received at least 1 dose of study drug.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 36.2 ± 10.6 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 0 |
| Male | 54 |
The record gives a start of Jan 2014, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran